Brief report: Lactobacillus bulgaricus GLB44 (Proviotic™) plus esomeprazole for Helicobacter pylori eradication: A pilot study |
| |
| Authors: | Antone R. Opekun Savannah A. Gonzales Mahmoud A. Al‐Saadi David Y. Graham |
| |
| Affiliation: | Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, USA |
| |
| Abstract: | Background Recent studies of Lactobacillus delbrueckii subsp. bulgaricus GLB44 plus a proton‐pump inhibitor (PPI) reported cures of more than 90% of patients with active Helicobacter pylori infections. Aim To confirm the high H. pylori cure rates reported previously. Method A pilot study was done in healthy H. pylori‐infected volunteers using 3‐gram sachet (3 billion cells) of L. delbrueckii GLB44 plus 22.3 mg of esomeprazole b.i.d., for 14 days. The result was determined by urea breath testing 4 weeks after therapy. Stopping rules required for ending enrollment if less than 3 of the first 10 subjects were cured. Results Nine subjects were entered and because all failed to achieve negative urea breath test, the stopping rule required the study to end. Conclusion We were unable to confirm reports of achieving a high H. pylori cure rate with L. delbrueckii GLB44 plus a PPI. |
| |
| Keywords: | clinical trial
Helicobacter pylori
Lactobacillus bulgaricus
probiotic therapy |
|
|
